

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)*

ANNOUNCEMENT CHANGE OF COMPOSITION OF THE BOARD COMMITTEES

The board of directors (the “**Board**”) of Sinopharm Group Co. Ltd. (the “**Company**”) hereby announces that Mr. Yang Binghua, an executive director of the Company, has been appointed as a member of the strategy and investment committee of the Board; Mr. Zu Jing, a non-executive director, and Mr. Wen Deyong, a non-executive director, have been appointed as members of the audit committee of the Board; Ms. Li Ying, a non-executive director, has been appointed as a member of the nomination committee of the Board; and Mr. Xing Yonggang, a non-executive director, has been appointed as a member of the legal and compliance and environmental, social and governance committee of the Board. The above appointments all take effect on 18 August 2026.

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
18 August 2026

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*